

Company Presentation 2025

We create value in Life Science and contribute to improved quality of life



























MedCap Snapshot

Revenue, million SEK 1789 EBITA margin 18.5%









MedCap | An active investor in Life Science companies

Last Twelve Months, Q3 2024

Sales by Business Area



Sales by Market





Our Model

Life Science

Sector focus
Network of expertise
Knowledge sharing
Market insight



Entrepreneurship

Decentralized & local responsibility
Integrity of acquired brands
Quick & agile, yet long-term mindset
Ambitious organic business plans

-Group Scale

Scalable business areas Merger & Acquisitions Governance – ESG Financing





Success factors

Solid markets

Non-cyclical

Demographic drivers

Market nisches

Market share potential



Active ownership

People & Management

Business objectives

Performance management

Bolt-on acquisitions





Examples of healthcare trends relevant to our business

	Assistive Tech	MedTech	Ar.	Specialty Pharma	Ę	
Consumer Health						
Health Economics & Regulations and Requirements						
Pharmaceutical shortages						
Screening, Diagnostic						
Digitalization, Connectivity, Use of data						
Home care, Telemedicine, Remote Monitoring						
Prevalence of Diagnoses & Chronic Conditions						
Demographics & Aging Population						



MedCap Business Areas












20 years of scaling businesses through M&A and investments









Investment strategy

Scope

Life Science

Assistive | MedTech | Pharma

Europe

Add-ons globally

Small / Mid-size Businesses

Sales <50 mEUR


Majority Owner

51-100% Ownership

Long-term

Buy & Build | No exit horizon

What we look for





Financial Targets

Annual EBITA growth

>15%

Return on Equity


>20%

Net debt / EBITDA


<3x



Financial Targets










How we track our financial targets in our businesses

Financial Objectives	Key Metrics In Our Businesses
>15% EBITA growth	Organic and acquisition driven sales growth (depending on maturity of business) Profit margins
Return on Equity >20%	Core Working Capital / Sales, Cash Conversion, EBITA / (Fixed assets & WC) Capex IRR, Pay-back Acquisition valuation
Net debt / EBITDA <3	Group level
Grow size of business	Sales growth Business development pipeline M&A Pipeline



Sales and EBITA rolling 12 months by quarter







Why MedCap?

1

Sustainable Industry

Life Science industry improves quality of life

MedCap's portfolio companies contributes to inclusion, care and healthcare

We strive to operate sustainable and work towards UN's sustainable development goals



2

Profitable Growth

Annual growth of 19% over the last 5 years

Annual EBITA growth of 29% over the last 5 years

Objective to increase EBITA by more than 15% per year

Objective to grow significantly; both organic and acquisitions

3

Proven & Scalable Model

Decentralized model – customer focused responsibility and decisions making

Combination of entrepreneurial drive in smaller companies and the strength of a larger group

Long-term value creation



4

Large & Growing Market

Fragmented market – many small and medium sized life science companies in Europe

Growing market – demographics as well as healthcare investments and innovation drives growth

Good possibilities for acquisitions





Thank You!





Anders Dahlberg CEO anders.dahlberg@medcap.se +46 704 269 262



Kristina Ekblad CFO kristina.ekblad@medcap.se +46 703 322 167

